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Abstract
Objective: To estimate the occurrence of acute events in hospitali-
zed patients with sickle cell anemia (SCA) before and after the use of 
hydroxyurea (HU). 
Method: The study has a quantitative approach, of analytical cohort 
type developed in two public referral hospitals in the Midwest region 
of Brazil, from November 2010 to October 2011. Data collection was 
performed on records of patients diagnosed with SCA. The inter-
val time for the data collection was 30 years, which corresponded 
between 1980 and 2010. The research was approved by the Ethics 
Committee of the Federal University of Mato Grosso do Sul, Campo 
Grande/MS, Brazil, under protocol 1822/2010. 
Results: The sample had 32 medical records of hospitalized patients 
diagnosed with SCA who used HU. The mean age of the participants 
was 25.65±11.92; the average time of drug exposure was 6.0±2.8 
years; the average initial dose was 17.00±5.3mg/kg/day and final dose 
of 22.10±5.3 mg/kg/day. After using HU, the fetal hemoglobin ranged 
from 8.41±0.95 to 14.44±13.7% (p<0.001). There was a reduction of 
the average leucocyte, absolute neutrophil, acute events, total infec-
tions and blood transfusions. 
Conclusion: The effects of HU exposure caused an increase in 
fetal hemoglobin level, decreasing leukocyte, absolute neutrophils 
and acute events, transfusions and hospitalizations by the use of 
non-opioid.
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Introduction
Sickle cell anemia (SCA) is a genetic disorder caused 
by the homozygous of gene βs encoding the he-
moglobin S (HbS). The HbS results from the sub-
stitution of glutamic acid (GAG) by valine (GTG) at 
position six of the globin β chain. This exchange 
results in profound changes in the physicochemi-
cal properties of the molecule of hemoglobin (Hb) 
when deoxygenated [1, 2]. Such changes occur in 
cell morphology, and the RBCs are an elongate form 
known as “sickle erythrocyte” altering the rheology 
of red blood cells and the erythrocyte membrane 
and results in the polymerization phenomenon 
[3, 4]. These changes culminate in two important 
pathophysiological processes of sickle cell anemia, 
hemolysis, and vase-occlusion [5].
The occurrence of the vase-occlusive episode is 
the pathophysiological event decisive for the origin 
of most of the signs and symptoms of the clinical 
picture of patients with SCA and other manifesta-
tions or acute events that are worth mentioning, 
as the painful crises, aplastic, hemolytic, pulmo-
nary complications, neurological and hepatobiliary 
as well as infections [6, 7]. From these events, the 
pain crisis is considered the most dramatic event in 
the picture of the disease [8].
The polymerization phenomenon is regulated by 
the level of HbS and decreasing with the presence 
of other forms of hemoglobin that does not contain 
mutant forms of the β globin. The main therapeutic 
approach to SCA is trying to change the produc-
tion of hemoglobin S for fetal hemoglobin (HbF), 
resulting in a less severe degree of symptoms and 
less hemolytic anemia [9]. For cases with an indica-
tion, the treatment with hydroxyurea (HU) may be 
instituted to ameliorate the clinical picture of the 
disease [10].
By its action, the HU elevates HbF and conse-
quently decreases the vase-occlusion and hemoly-
sis, resulting in the reduction of the frequency of 
transfusions, painful events, number, and duration 
of hospitalization. This treatment further enhances 
the hematological parameters and increases nitric 
oxide concentrations, depending on the inhibitory 
role of HbS polymerization [11]. The effective thera-
peutic action is observed in observational studies 
[12] and demonstrated in Randomized Clinical Trial 
(RCT) with serious adults [13].
The benefits of using HU found that early drug 
exposure to the patient brings a greater likelihood 
of mortality prevention [14]. Given the above, this 
study aimed to estimate the occurrence of acute 
events in hospitalized patients with sickle cell ane-
mia before and after the use of hydroxyurea as a 
treatment option.
Method
This is a study with a quantitative approach, of the 
analytical cohort type developed in two public refe-
rral hospitals in the Midwest Brazil, from November 
2010 to October 2011.
Data collection was performed on records of pa-
tients diagnosed with sickle cell anemia (HbSS). The 
interval time for the data collection was 30 years, 
which corresponded between 1980 and 2010. Pa-
tients with at least 24 hours of hospitalization, with 
a diagnosis of sickle cell anemia confirmed by he-
moglobin electrophoresis and having a medical in-
dication for HU treatment were included.
The hematological variables collected were: fe-
tal hemoglobin (HbF); total hemoglobin concentra-
tion; hematocrit; erythrocytes or RBCs; leukocytes, 
absolute neutrophils, and platelets, collected befo-
re and after the HU use. The evaluation of labora-
tory parameters in this study followed the values 
espoused by Failace [15] Falcão and Calado [16]. 
The absolute number of neutrophils is the total of 
neutrophils about leukocytes [15], calculated using 
the formula: absolute neutrophil = neutrophils x 
leukocytes/100.
The clinical variables collected were: hydroxyu-
rea (starting date, age at the beginning of the 
treatment, initial dose, final dose and average ex-
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posure time) and acute events before and after 
the use of HU (pain crises, acute chest syndrome/
pneumonias - STA/pneumonias), infections, sepsis, 
priapism, stroke, cholelithiasis, aplastic crisis and the 
number of blood transfusions). Other variables were 
related to hospitalizations using opioid analgesics, 
non-opioid analgesics.
The acute events were defined according to cri-
teria established by the Ministry of Health of Brazil. 
[17] In the variable of acute events, all events were 
included, including pain crisis. It was opted for this 
study to analyze the frequency of painful crisis as an 
independent variable separately. Moreover, in the 
variable infections, all infections are included in ge-
neral, including pneumonia. It was also decided to 
examine separately pneumonia to be more frequent 
infections in sickle cell disease.
For the relationship of individualized mg/kg to the 
HU dosage, the data on the weight of each patient 
and the prescribed dose recorded in the medical 
record were used, both before and after use.
When analyzing the results, the comparison 
between the moments before and after the use 
of HU was performed using the Wilcoxon test 
when the samples did not pass the normality test, 
or through the t Student test when they passed 
the normality test. The other results of the va-
riables evaluated in this study were presented in 
descriptive statistics. The statistical program used 
was SigmaStat, version 3.5 and the level of signi-
ficance was p <0.05.
The study was previously evaluated and approved 
in its ethical, and methodological aspects by the 
Ethics Committee in Research of the Federal Uni-
versity of Mato Grosso do Sul, Campo Grande/MS, 
Brazil, under protocol 1822/2010.
Results 
The sample was 32 medical records of hospitalized 
patients diagnosed with SCA who used HU. The 
mean age of subjects was 25.65±11.92, which in-
dicates that most of the patients were in the third 
decade of life. The average time of exposure to 
drug was 6.0±2.8 years, and the mean initial dose 
was 17.00±5.3mg/kg/day, and the final dose was 
22,10±5.3mg/kg/day.
Figure 1 shows the percentage of HbF level 
reached in this sample after using HU. This re-
sult demonstrates the effectiveness of the drug, 
which resulted in a significant increase in HbF (p 
<0.001).
The leukocytes showed a significant reduction in 
the use of hydroxyurea (Table 1).
Figure 1:  Fetal hemoglobin percentage (HbF) in 
patients with sickle cell anemia before 
and after the use of hydroxyurea.
*: Significant difference from the time before using hydroxyurea 
(t Student test, p<0,001).
Table 1.  Hematological parameters in patients with 
sickle cell anemia before and after the use 
of hydroxyurea between 1980 and 2010.
Campo Grande/MS, Brazil, 2016 (n=32). 
Variable
Time regarding the use of hydroxyurea
P-value
Before1 After1
Hemoglobin 
(g/dL) 8.08±0.22 8.04±0.22 0.973
Hematocrit 
(%)
25.30±0.64 24.55±0.66 0.465
Erythrocytes 
(106/μL)
2.7±78544.01 2.5±77034.80 0.119
Leukocyte 
(103/μL)
15.986±1044.72 13.984±947.32 0.04222
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In Table 2, there are the results for the mean and 
standard deviation of clinical variables, normalized 
to a period of 10 years in hospitalized patients with 
sickle cell anemia before and after the use of HU. 
After the drug use, there was a significant reduction 
in hospitalizations for treatment with non-opioid 
analgesics in acute events infections, pneumonia 
and blood transfusions.
Discussion
After using HU, there was a significant increase 
in HbF level of 8.41±0.95 to 14.44±1.37%, with 
an initial medication dosage of 17mg/kg/day and 
final dose of 22.10mg/kg/day. The results of this 
study demonstrated the effectiveness of medicine 
treatment for SCA. These findings are like tho-
se found in an observational study that evaluated 
the pharmacokinetics, toxicity and HbF production 
with a sample of 32 HbSS patients. In this study, 
the mean age ranged from 27.60±6.3 years, but 
the initial dosage was 10mg/kg/day and ranged up 
to 35mg/kg/day, as there was a significant increase 
in HbF of 4±2 to 15±6% after its use, p<0.001 
[12].
In adults, g globin genes have a normal se-
quence, but remain almost inactive at this stage. 
However, in exceptional conditions, these genes 
are activated to produce red blood cells with highly 
enriched Hb, composed of α and g chains called as 
HbF. The HU acts while acting in g globin genes 
from primitive progenitors and it forces the pro-
duction of F. This process causes cells to change 
the kinetics of erythroid proliferation, and produc-
es nitric oxide that acts directly in the production 
of HbF. [9]
The use of HU in patients with sickle cell anemia 
is the result of research carried out at the end of 
the 1970s, in which it was demonstrated that the 
change in vivo of the erythropoiesis kinetic arises 
from the HU when inducing the production of fetal 
hemoglobin [18].
Interestingly, erythrocytes, hemoglobin, and he-
matocrit with averages already reduced before the 
use of HU did not increase after treatment with the 
drug. These results differ from those observed in 
another study which varied dosage of 10mg/kg/day 
to 35mg/kg/day performed in people with sickle cell 
disease [12].
In this study, the leukocytosis showed a signifi-
cant reduction in the use of HU. These findings 
corroborate the research that highlighted the key 
role of leukocytes in the oxidative and inflamma-
tory stress process. Accordingly, leukocytosis may 
occur due to increased levels of cytokines my-
Variable
Time regarding the use of hydroxyurea
P-value
Before1 After1
Absolute 
neutrophil 
(mL) 
11157.32±908.64 10070.20±742.32 0.185
Platelets 
(103μL)
277.964.29±21087.34 320.160.00±20842.72 0.278
1: Data are presented as mean±standard error of the mean. 
2: p-value with a significant difference between the times before and 
after use of hydroxyurea.
Table 2.  Average number of hospitalizations and 
acute events (normalized to a period of 
10 years) seen in patients with sickle cell 
anemia before and after the use of hydro-
xyurea between 1980 and 2010. Campo 
Grande/MS, Brasil, 2016 (n=32).
Variable
(Average every 10 years)
Time regarding the use of 
hydroxyurea P-value
Before1 After1
Interactions with non-
opioid analgesics 10.65±1.76 6.51±1.29 0.014
2
Interactions with opioid 
analgesics
7.34±1.27 5.27±1.03 0.127
Acute events 14.16±2.62 7.05±1.48 0.0142
Pain crises 8.20±1.47 5.32±1.17 0.264
Infections 1.58±0.52 0.35±0.17 0.0052
Pneumonias 2.80±0.79 0.79±0.36 0.0122
Blood transfusions 20.12±4.56 10.43±2.10 0.0372
1: Data are presented as mean±standard error of the mean. 
2: p-values significant difference between before and after the use 
of hydroxyurea (Wilcoxon Test).
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eloid proliferative and delayed apoptotic process 
[19]. Furthermore, leukocytes play a central role 
in initiating vase-occlusive event since from these 
cells there is the aggregation of other blood cells 
(erythrocytes, platelets) that promote the narrow-
ing of the vessel lumen. This phenomenon affects 
the circulation and leads to hypoxia. In response, 
leukocytes will produce cytokines that induce the 
expression of adhesion molecules by vascular en-
dothelium [20].
The absolute neutrophils showed a small reduc-
tion in their average values. In a study of patients 
diagnosed with SCA residents in the United States 
and Canada it was found that after two years of 
therapy with HU, there were half of the patients 
with an increase in HbF with reduced leukocytes 
and consequent improvement of the disease in the 
experimental group [13].
In this study, the acute events showed a signifi-
cant reduction in the average after the use of HU. 
The effect of this drug reduces the incidence of 
vase-occlusive crisis supposedly by elevated HbF, 
with improvement in patients´ symptoms [21]. Evi-
dence of the effect of HU is demonstrated with 
the explosion of young F cells within 72 hours [22].
The reduction of acute events after the use of 
HU emphasizes the complexity of the vase-occlusive 
process in sickle cell anemia, not completely un-
derstood condition and participation of neutrophil 
as the vase-occlusive event initiators. In this sense, 
polymorphonuclear neutrophils (PMN) are activated 
by direct interaction sickled erythrocytes (SS-RBC), 
which takes the PMN to play a crucial role in the 
cascade of events leading up to the crisis. Therapeu-
tic interventions intended to reduce SS-RBC-PMN 
[21].
As for the total of acute events in this study, 
there was a reduction in the use of HU. In a Brazil-
ian study, there was a reduction of three events: 
painful crises (1.86 to 0.81, p=0.0014), acute chest 
syndrome (from 0.35 to 0.08, p=0.0045, infections 
(1.03 to 0.5, p=0.047) [23].
In this study, pain crises did not show a signifi-
cant reduction, but its frequency decreased after 
using HU. In addition to this event, there was a sig-
nificant reduction in the mean of transfusions and 
hospitalizations. These results corroborate an RCT 
developed with 299 patients, in which there was a 
reduction in crisis rate in treated patients (mean 2.5 
vs. 4.5 crises/year, p<0.001) compared to placebo, 
as well as in transfusions and hospitalizations [13]. 
A systematic review study aimed at identifying in 
the literature and gathering the scientific evidence 
showing effectiveness, barriers, and toxicity of the 
use of HU in children with SCA, also found reduced 
pain episodes and hospitalizations [24]. Another re-
view gathered scientific evidence on the manage-
ment of sickle cell disease, and it strongly recom-
mends the use of hydroxyurea for adults with 3 or 
more vase-occlusive crises per year, with episodes of 
pain that interfere with their daily lives. [25]
Regarding the hospitalizations for treatment of 
acute events with opioid analgesics and non-opioid 
after using HU, there was an average reduction in 
the frequency requirements of these analgesics and 
significant reduction of the use of non-opioids. In 
the therapeutic approach, morphine is the opioid 
agonist most widely used for pain control, and me-
peridine is contraindicated for patients with sickle 
cell disease, because there may be physical depen-
dence [8].
In infections, there was a significant reduction of 
the mean values in this study after using HU. In a 
survey of 43 children with sickle cell anemia (93% 
asplenia or almost asplenia), the spleen filtering 
function was measured before and during therapy 
with maximally tolerated dose of HU and average 
use of 2.6 years. Of this total, six patients (14%) had 
the spleen function completely recovered [26]. The 
spleen in the initial state of hipoesplenia presented 
reversibility function in response to certain treat-
ments such as hydroxyurea [27].
The most frequent acute event among the in-
fections in the sample studied was pneumonia. To 
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discuss this finding, it was based on a retrospective 
study that showed an incidence of 16% of serious 
bacterial infections, mostly pneumonia being with-
out records in the use of HU [28, 29].
Limitations of this study are related to some 
variables that were not systematically in the re-
cords and prevented them from making some 
interesting analysis. It is emphasized that these 
limitations did not prevent achieving the goal of 
current research.
Conclusion
The results of this study showed that after the use 
of hydroxyurea in patients with sickle cell anemia 
(SCA), there was a significant increase in the level 
of HbF, significant reduction in mean leukocyte val-
ues, absolute neutrophils, as well as in acute events, 
transfusions and hospitalizations for use non-opioid 
in the sample investigated. It is suggested to carry 
out further studies with an experimental approach 
to find what is the ideal dose of HU to be adminis-
tered to patients with sickle cell anemia.
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